AAAAAA

   
Results: 1-8 |
Results: 8
A CONTROLLED TRIAL OF REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE
Authors: KIEBURTZ K FEIGIN A MCDERMOTT M COMO P ABWENDER D ZIMMERMAN C HICKEY C ORME C CLAUDE K SOTACK J GREENAMYRE JT DUNN C SHOULSON I
Citation: K. Kieburtz et al., A CONTROLLED TRIAL OF REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE, Movement disorders, 11(3), 1996, pp. 273-277
EFFECT OF LAZABEMIDE ON THE PROGRESSION OF DISABILITY IN EARLY PARKINSONS-DISEASE
Authors: KIEBURTZ K MCDERMOTT M SHOULSON I FAHN S BRIN M GOETZ C LANG A OLANOW CW LEWITT P MISTURA K WATERS C WELSH M RODNITZKY R DOBSON J ARGATOFF P TANNER C LEWIS P WATTS R BRYAN B COMELLA C JAGLIN JA SHULTS C FONTAINE D BRESSMAN SB MOSKOWITZ C HURTIG HI SHALLOW K HUBBLE J BARTER R BENNETT JP ROSTRUFFNER E PERLMUTTER JS MCGEEMINNICH L HAUSER R GAUGER L RAJPUT AH SUTTON A TRINIDAD K GARDINER IF SINGER C SHELDON C FINK JS TENNIS M BAKER D BOURGEOIS K CASACELI C CLAUDE K HICKEY G NOBEL R OAKES D ORME C PELUSIO RM PLUMB S RUDOLPH A RANDOLPH P SOTACK J WATTS A TARIOT PN GOLBE LI MILLER P HALL WJ HERNDON R DORFLINGER E MYL D MODI M OARSLEY L YOO K ELIAHOU E SHIMOUN G COLLETTA S SIEGEL J PEDDER S DUPUIS D
Citation: K. Kieburtz et al., EFFECT OF LAZABEMIDE ON THE PROGRESSION OF DISABILITY IN EARLY PARKINSONS-DISEASE, Annals of neurology, 40(1), 1996, pp. 99-107
IMPACT OF DEPRENYL AND TOCOPHEROL TREATMENT ON PARKINSONS-DISEASE IN DATATOP SUBJECTS NOT REQUIRING LEVODOPA
Authors: SHOULSON I FAHN S OAKES D LANG A LANGSTON JW LEWITT P OLANOW CW PENNEY JB TANNER C KIEBURTZ K KOLLER W RODNITZKY R FINK JS GROWDON JH PAULSON G KURLAN R FRIEDMAN JH GANCHER S NUTT J RAJPUT AH BENNETT JB WOOTEN GF GOETZ C SHANNON K SUCHOWERSKY O BRIN MF BRESSMAN SB WEINER WJ SANCHEZRAMOS J JANKOVIC J HOEHN M TETRUD J GRIMES JD PFEIFFER R SHULTS C THAL L GAUTHIER S GOLBE LI PERLMUTTER JS MOSES H REICH SG HURTIG HI STERN M BARTER R VETEREOVERFIELD B GAUGER L MALAPIRA T DOBSON J ATAMIAN S TENNIS M COHEN JB DESCLOS G HOFFMAN E DENIO L HUBER S WOIKE T ZOOG K MENDELL R DUDTE K BEHR J GARDINER IF LANNON M CARTER J NORTHRUP S KANIGAN B TURK M LANDOW E SCHLICK P MISTURA K CARROLL VS THELEN JA DEMONG C WINFIELD L MOSKOWITZ C INGENITO A SHELDON C CORNELIUS L HEIBERG D DUNNE C BRADY J KIERANS C BELLESCANTLEBURY L DUFF J WEBER H SAVOINI D LEWIS P KUTNER SJ GRAY P GLAESKE C HOFMAN R PAY MM SALMON D MCFAUL F AMYOT D BERGEN M MCGEEMINNICH L ODONNELL P FERRISE S SHALLOW K BAKER D CASACELI C EBERLY S MCDERMOTT M NOBEL R ORME C PELUSIO RM PLUMB S RUDOLPH A RANDOLPH H SOTACK J WATTS A
Citation: I. Shoulson et al., IMPACT OF DEPRENYL AND TOCOPHEROL TREATMENT ON PARKINSONS-DISEASE IN DATATOP SUBJECTS NOT REQUIRING LEVODOPA, Annals of neurology, 39(1), 1996, pp. 29-36
FUNCTIONAL DECLINE IN HUNTINGTONS-DISEASE
Authors: FEIGIN A KIEBURTZ K BORDWELL K COMO P STEINBERG K SOTACK J ZIMMERMAN C HICKEY C ORME C SHOULSON I
Citation: A. Feigin et al., FUNCTIONAL DECLINE IN HUNTINGTONS-DISEASE, Movement disorders, 10(2), 1995, pp. 211-214
EVIDENCE OF THE GLUTAMATE ANTAGONIST REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE
Authors: KIEBURTZ K MCDERMOTT M MARSHALL FJ FEIGIN A COMO P ABWENDER D ZIMMERMAN C HICKEY C ORME C BORDWELL K SOTACK J GREENAMYRE JT DUNN C SHOULSON I
Citation: K. Kieburtz et al., EVIDENCE OF THE GLUTAMATE ANTAGONIST REMACEMIDE HYDROCHLORIDE IN HUNTINGTONS-DISEASE, Neurology, 45(4), 1995, pp. 254-254
AN OPEN-LABEL TRIAL OF COENZYME-Q10 (COQ) IN HUNTINGTONS-DISEASE (HD)
Authors: FEIGIN A KIEBURTZ K COMO P ABWENDER D ZIMMERMAN C HICKEY C STEINBERG K BORDWELL K SOTACK J ORME C SHOULSON I
Citation: A. Feigin et al., AN OPEN-LABEL TRIAL OF COENZYME-Q10 (COQ) IN HUNTINGTONS-DISEASE (HD), Neurology, 44(4), 1994, pp. 10000397-10000398
TRINUCLEOTIDE REPEAT LENGTH AND PROGRESSION OF ILLNESS IN HUNTINGTONS-DISEASE
Authors: KIEBURTZ K MACDONALD M SHIH C FEIGIN A STEINBERG K BORDWELL K ZIMMERMAN C SRINIDHI J SOTACK J GUSELLA J SHOULSON I
Citation: K. Kieburtz et al., TRINUCLEOTIDE REPEAT LENGTH AND PROGRESSION OF ILLNESS IN HUNTINGTONS-DISEASE, Journal of Medical Genetics, 31(11), 1994, pp. 872-874
A CONTROLLED TRIAL OF LAZABEMIDE (RO-19-6327) IN LEVODOPA-TREATED PARKINSONS-DISEASE
Authors: KIEBURTZ K MCDERMOTT M SHOULSON I OAKES D FAHN S LANG A PENNEY JB RODNITZKY R SHULTS C TANNER C TETRUD J GORDON M LEWITT P BENNETT J KOLLER W FRIEDMAN JH KURLAN R OBRIEN C MARK MH WEINER WJ SANCHEZRAMOS J PAULSON G COMELLA C JANKOVIC J OLANOW W SHANNON K LEWIS P WINFIELD L CIECIERSKI K MISTURA K LANDOW E DIETRICH S GEBHARDT AM BARTER R KENNEDY D CULLEN KA GARDINER IF BERGEN M PATTERSON V FABRIELE M SHELDON C CORNELIUS L DUDTE K THELEN JA DUNNE C GAUGER L MALAPIRA T COURVILLE K TROTTER H PELUSIO RM RUDOLPH A CASACELI C MILLER C BOETTRICH C CONNORTON J BYRNE L ORME C BORDWELL K MCMANUS J SOTACK J RANDOLPH H KAVANAUGH B BAKER D RUMFOLA L NOBEL R EBERLY S PLUMB S WATTS A GERWITZ K DARCY S EVANS P FREDERICK D DELLAPENA L SINGLETARY V TARIOT P BELL E GRIGGS RC HALL WJ HERNDON R MARSDEN CD CHASE TN COHEN G FLEISS J JACOBS L MOSS AJ MELAMED E DORFLINGER E YOO K SHIMOUN G MORAWSKY L
Citation: K. Kieburtz et al., A CONTROLLED TRIAL OF LAZABEMIDE (RO-19-6327) IN LEVODOPA-TREATED PARKINSONS-DISEASE, Archives of neurology, 51(4), 1994, pp. 342-347
Risultati: 1-8 |